Evidence map›Paper›PMID 32042862›Full record

ReviewGenes & diseases2019

Paradox-driven adventures in the development of cancer immunology and immunotherapy.

Whitney Barham, Joanina K Gicobi, Yiyi Yan, Roxana S Dronca, Haidong Dong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Genes & diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Modeling multi-needle injection into solid tumor.American journal of cancer research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Whitney BarhamMayo Clinic Medical Scientist Training Program, Mayo Clinic, Rochester, MN, USA.
Joanina K GicobiMayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.
Yiyi YanDepartment of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
Roxana S DroncaDivision of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.
Haidong DongDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.

Funding

Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
NIGMS NIH HHS T32 GM065841
6 · The paper itself

Abstract

After more than one hundred years of documented trials, immunotherapy has become a standard of care in the treatment of human cancer. Much of the knowledge that led to recent breakthroughs seems quite logical from today's point of view. However, what we now cite as facts were originally considered

Indexed as

BiomarkerCancer immunotherapyCytotoxic T cellsHyperprogressionImmune checkpointsPD-1PD-L1

Identifiers

PMID32042862
PMCPMC6997591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.